Midatech has three platform technologies that are focused on improving bio-distribution and bio-delivery of medications in different ways – either via sustained delivery, targeted delivery, or direct delivery.
Sustained delivery is achieved using our polymer microsphere technology Q-Sphera™, which is based on our disruptive micro-piezo print production inovation to individually print drug-loaded microspheres in the size range 20-50µm, at a rate of several million spheres per second. Microsphere dimensions are consistently monodispersed and homogenous, and can be thus be finely tuned to accurately customise drug release rates. Reliable and precise encapsulation enables drug release into the body in a highly controlled and predictable manner over a prolonged period of time, from a few weeks to more than six months. Q-Sphera microspheres have improved injectability characteristics compared to traditional manufacturing methods, requiring a much simpler, error free and shorter reconstitution process. The monodispersed particles avoid needle blockage, and facilitate the use of smaller gauge needles with reduced injection pain. Q-Sphera formulations typically yields consistent and reproducible blood and local tissue drug concentrations within tight limits.
Direct delivery is achieved using our nano saccharide technology MidaSolve, which effectively allows insoluble medications to be converted from a solid tablet form for oral ingestion, to a dissolved liquid form that can then be infused directly into the tumour. The N-Circ complexes are particularly stable, with a significant increase in the aqueous solubility of the compound at biological pH. The technology increases the possible routes of administration and uses from an oral only route to a liquid form that can be given parenterally into the body or tumour directly.
Targeted delivery is achieved using our gold nanoparticle technology MidaCore®, a leading innovation in ‘ultra-small’ nanomedicine, enabling improved delivery of therapeutics to tumor cells and the immune system. In oncology treatments MidaCore® provides a nano complex (less than 5nm in size) that carries conventional small molecule chemo-therapeutic payloads and delivers these to the tumour site in high concentrations. In immune-oncology treatments, MidaCore acts as a nano carrier complex for synthetic immuno-peptides to seek out cancer cell-surface proteins via immune mediated peptide vaccines. These small complexes can enter immune processing cells to induce T-cell mediated immune responses specifically against tumour cells, viral infected host cells or autoimmune disease.